Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 2,476 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HSCT Clear all

Conditions: Sinusoidal Obstruction Syndrome
Interventions: Serial Blood Draws; Other
Lead sponsor: Indiana University; Other
Eligibility: Up to 25 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: clofarabine, melphalan, gene expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation; Drug · Genetic · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 1 Year to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Duarte, California

Conditions: Bone Marrow Transplantation, Blood Disease, Hematopoietic Stem Cell Transplantation, Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Graft vs Host Disease
Interventions: fluconazole, voriconazole, bone marrow transplant, thalidomide, dexamethasone; Drug · Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 16
States / cities: Duarte, California • La Jolla, California • Palo Alto, California + 13 more

Conditions: Leukemia
Interventions: sargramostim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, imatinib mesylate, leucovorin calcium, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 15 Years to 65 Years
Enrollment: 1,929 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1993
U.S. locations: 94
States / cities: Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 63 more

Conditions: Multiple Myeloma, Lymphoma, Transplant-Related Disorder
Interventions: Feedback; Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Mantle Cell Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human; Procedure · Biological
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years to 70 Years
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 374
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 236 more

Conditions: AL Amyloidosis
Interventions: Bortezomib, Melphalan, Neupogen, Stem Cell Collection, Stem cell infusion; Drug · Procedure
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stem Cell Transplantation
Interventions: Fludarabine, Dexamethasone, Cyclophosphamide, Bortezomib, Rituximab, Busulfan, Cyclophosphamide (Cy), Tacrolimus (or cyclosporine), Mycophenolate mofetil (MMF), Rabbit ATG; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mucopolysaccharidosis Type I (MPS I), Mucopolysaccharidosis Type II (MPS II), Mucopolysaccharidosis Type III (MPS III), Mucopolysaccharidosis Type VI (MPS VI), Krabbe Disease
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 1 Day to 18 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 3
States / cities: Chicago, Illinois • Minneapolis, Minnesota • Buffalo, New York

Conditions: Multiple Myeloma
Interventions: Iberdomide, Lenalidomide; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 44
States / cities: Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 34 more

Conditions: Diffuse Large Cell Lymphoma, Lymphoma
Interventions: Zevalin, Carmustine, Etoposide, Cytarabine, Melphalan, Rituximab, Stem Cell Transplant; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bone Marrow Ablation, Leukemia
Interventions: filgrastim, etoposide, peripheral blood stem cell transplantation, low-LET electron therapy, low-LET photon therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 16 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Myeloma, Plasma-Cell, Lymphoma, Malignant
Interventions: Palonosetron, Aprepitant, Dexamethasone; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Acute Graft-Versus-Host Disease (Gvhd) Grade, Hematopoietic Cell Transplantation, Fecal Microbiota Transplant
Interventions: Fecal Microbiota Transplant; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Eltrombopag; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cytomegalovirus Infection
Interventions: mRNA-1647, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • St Louis, Missouri • Seattle, Washington

Conditions: Leukemia
Interventions: Filgrastim, Busulfan, Cyclophosphamide, Cyclosporine, Decitabine (DAC), Methotrexate, Methylprednisolone, Tacrolimus, Allogeneic Bone Marrow Transplantation, Peripheral Blood Stem Cell Transplantation; Biological · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: filgrastim, sargramostim, busulfan, carboplatin, cyclophosphamide, melphalan, paclitaxel, tamoxifen citrate, thiotepa, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Graft-versus-host Disease
Interventions: Interleukin-2; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Brain and Central Nervous System Tumors
Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 3 Years to 20 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2007
U.S. locations: 2
States / cities: Memphis, Tennessee • Houston, Texas

Conditions: Sickle Cell Disease, Thalassemia, Beta, Thalassemia
Interventions: Fludarabine, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Rabbit ATG, Dexamethasone, Bortezomib, Rituximab; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 2 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection
Interventions: Laboratory Biomarker Analysis, Leukapheresis; Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Bone Metastases
Interventions: 153 Sm-EDTMP, Questionnaire, Stem Cell Transplant; Drug · Behavioral · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: DS (Durie/Salmon) Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Desipramine Hydrochloride, Filgrastim, Laboratory Biomarker Analysis; Drug · Biological · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

Sinusoidal Obstruction Syndrome for Stem Cell Transplant Patients Biomarker Study

Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes

Blood and Marrow Transplant Clinical Research Network

Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission

Stepping Up: A Trial of Activity Monitoring Devices in Patients Undergoing Autologous Stem Cell Transplant

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

Lysosomal Storage Disease: Health, Development, and Functional Outcome Surveillance in Preschool Children

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission

Multi-day Doses in Prevention of Nausea and Emesis

FMT In High-Risk Acute GVHD After ALLO HCT

Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer

Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer

Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases

Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant